> Detailanzeige

Giacomucci, Giulia; Mazzeo, Salvatore; Bagnoli, Silvia; Casini, Matteo; Padiglioni, Sonia; Polito, Cristina; Berti, Valentina; Balestrini, Juri; Ferrari, Camilla; Lombardi, Gemma; Ingannato, Assunta; Sorbi, Sandro; Nacmias, Benedetta; Bessi, Valentina

Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
  • Beteiligte: Giacomucci, Giulia; Mazzeo, Salvatore; Bagnoli, Silvia; Casini, Matteo; Padiglioni, Sonia; Polito, Cristina; Berti, Valentina; Balestrini, Juri; Ferrari, Camilla; Lombardi, Gemma; Ingannato, Assunta; Sorbi, Sandro; Nacmias, Benedetta; Bessi, Valentina
  • Erschienen: MDPI AG, 2021
  • Erschienen in: Journal of Personalized Medicine
  • Sprache: Englisch
  • DOI: 10.3390/jpm11010047
  • ISSN: 2075-4426
  • Schlagwörter: Medicine (miscellaneous)
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Background: The aims of this study were to compare the diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of different cerebrospinal fluid (CSF) amyloid biomarkers and amyloid-Positron Emission Tomography (PET) in patients with a clinical diagnosis of Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD); to compare concordance between biomarkers; and to provide an indication of their use and interpretation. Methods: We included 148 patients (95 AD and 53 FTD), who underwent clinical evaluation, neuropsychological assessment, and at least one amyloid biomarker (CSF analysis or amyloid-PET). Thirty-six patients underwent both analyses. One-hundred-thirteen patients underwent Apolipoprotein E (ApoE) genotyping. Results: Amyloid-PET presented higher diagnostic accuracy, sensitivity, and NPV than CSF Aβ1–42 but not Aβ42/40 ratio. Concordance between CSF biomarkers and amyloid-PET was higher in FTD patients compared to AD cases. None of the AD patients presented both negative Aβ biomarkers. Conclusions: CSF Aβ42/40 ratio significantly increased the diagnostic accuracy of CSF biomarkers. On the basis of our current and previous data, we suggest a flowchart to guide the use of biomarkers according to clinical suspicion: due to the high PPV of both amyloid-PET and CSF analysis including Aβ42/40, in cases of concordance between at least one biomarker and clinical diagnosis, performance of the other analysis could be avoided. A combination of both biomarkers should be performed to better characterize unclear cases. If the two amyloid biomarkers are both negative, an underlying AD pathology can most probably be excluded.</jats:p>
  • Zugangsstatus: Freier Zugang